220 related articles for article (PubMed ID: 28213730)
1. Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy.
Mizuno R; Miyajima A; Hibi T; Masuda A; Shinojima T; Kikuchi E; Jinzaki M; Oya M
Med Oncol; 2017 Apr; 34(4):47. PubMed ID: 28213730
[TBL] [Abstract][Full Text] [Related]
2. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
[TBL] [Abstract][Full Text] [Related]
3. Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Song Y; Du C; Zhang W; Sun Y; Yang L; Cui C; Chi Y; Shou J; Zhou A; Wang J; Sun Y
Urol Oncol; 2016 Jun; 34(6):258.e15-22. PubMed ID: 26803435
[TBL] [Abstract][Full Text] [Related]
4. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
5. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?
Steffens S; Grünwald V; Ringe KI; Seidel C; Eggers H; Schrader M; Wacker F; Kuczyk MA; Schrader AJ
Oncologist; 2011; 16(11):1565-71. PubMed ID: 22020210
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.
Miyake H; Harada K; Ozono S; Fujisawa M
Mol Diagn Ther; 2016 Aug; 20(4):385-92. PubMed ID: 27178184
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
8. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
9. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
11. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
12. Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors.
Kumano M; Miyake H; Harada K; Fujisawa M
Med Oncol; 2013 Dec; 30(4):745. PubMed ID: 24122255
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Tyrosine Kinase Inhibitor
Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
[TBL] [Abstract][Full Text] [Related]
14. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
Miyake H; Harada KI; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522
[TBL] [Abstract][Full Text] [Related]
16. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
Gravis G; Chanez B; Derosa L; Beuselinck B; Barthelemy P; Laguerre B; Brachet PE; Joly F; Escudier B; Harrison DJ; Laird A; Vasudev N; Ralph C; Larkin J; Lote H; Salem N; Walz J; Thomassin J; Sfumato P; Stewart GD; Boher JM;
Urol Oncol; 2016 Apr; 34(4):167.e17-23. PubMed ID: 26670200
[TBL] [Abstract][Full Text] [Related]
17. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
18. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
Miyazaki A; Miyake H; Harada K; Fujisawa M
Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy.
Takamatsu K; Mizuno R; Omura M; Morita S; Matsumoto K; Shinoda K; Kosaka T; Takeda T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
Clin Genitourin Cancer; 2018 Aug; 16(4):e927-e933. PubMed ID: 29678472
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
Kubackova K; Melichar B; Bortlicek Z; Pavlik T; Poprach A; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Prausova J; Buchler T;
Target Oncol; 2015 Dec; 10(4):557-63. PubMed ID: 25903462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]